Document:

Summary of Director Compensation

 EXHIBIT 10.6 
 ICAGEN, INC. 
 Summary of Director Compensation 
 Compensation of our Directors  
 Icagen, Inc.
(the “Company”) reimburses non-employee directors for out-of-pocket expenses they incur in attending Board and committee meetings and pays each non-employee director an annual retainer fee. The Chairmen of the Company’s Audit,
Compensation and Nominating/Corporate Governance Committees receive an additional annual retainer. For 2008, the annual retainer fee for all non-employee directors was $25,000, and the annual retainer for the Chairmen of the Audit, Compensation and
Nominating/Corporate Governance Committee was $10,000, $3,000, and $3,000, respectively. On March 5, 2009, the Company’s Board of Directors, upon recommendation of the Compensation Committee, approved a 50% reduction in annual retainer
fees from their 2008 levels. Accordingly, the annual retainer fees for 2009 for all non-employee directors will be $12,500 and the annual retainer fee for the Chairmen of the Audit, Compensation and Nominating/Corporate Governance Committees will be
$5,000, $1,500 and $1,500, respectively. 
 The Company also pays each non-employee director $1,000 for attendance at each Board meeting in
which he or she participates in person or $500 if attendance is by telephone. Each non-employee director also receives $1,000 for each meeting of a committee of the Board that is held on a day other than the day of any meeting of the full Board of
Directors if he or she participates in person, or $500 if attendance is by telephone. Directors who are also the Company’s employees do not receive any compensation in their capacities as directors. 
 Upon the commencement of service on the Board by any non-employee director, the Company grants to such person a non-statutory stock option to purchase
the number of shares of the Company’s common stock equal to the product of (i) 10,000 shares of the Company’s common stock divided by 12 and (ii) the number of full calendar months between the date of commencement of service and
the month in which the Company’s next annual meeting of stockholders is scheduled to occur. Each of the Company’s non-employee directors is also automatically granted a non-statutory stock option to purchase 10,000 shares of the
Company’s common stock every year on the first business day after the Company’s Annual Meeting of Stockholders. In addition, the Company’s Chairman of the Board of Directors receives a non-statutory stock option to purchase 20,000
additional shares of the Company’s common stock every year on the first business day after the Company’s Annual Meeting of Stockholders. All of these options are fully vested on the date of grant and have exercise prices equal to the
closing price of the Company’s common stock on the date of grant. 
 To compensate non-employee directors for the reduction in annual
retainer fees discussed above, on March 5, 2009, the Board of Directors, upon recommendation of the Compensation Committee, granted each of the Company’s non-employee directors a number of restricted stock units, or RSUs, equal to
(i) the dollar amount by which the annual retainer fee for 2008 was reduced, taking into account fees received by such director for service as a chairman of a committee of the Board, divided by (ii) $0.47, the closing price of the
Company’s common stock on that date. Each RSU represents the right to receive in the future one share of the Company’s common stock, subject to the terms and conditions of the applicable restricted stock unit agreement. These RSUs will
vest in full on December 31, 2009. If a director ceases to serve as a member of the Company’s Board of Directors for any reason prior to that date, all RSUs will automatically terminate and be forfeited as of the date such person ceases to
serve as a member of the Board. In addition, upon the occurrence of a change of control of Icagen, each RSU will immediately become fully vested. 
 At a meeting of the Board on March 5, 2009, Dr. Gillings elected to decline the RSU grant described above as well as all annual retainer fees that he would otherwise be entitled to for the remainder of 2009 as compensation for his
Board service. 
 The Compensation Committee and the Board of Directors of the Company periodically reevaluate compensation of the
Company’s non-employee directors and may modify such compensation as they deem appropriate.Summary of 2009 Bonus Targets

 EXHIBIT 10.7 
 ICAGEN, INC. 
 Summary of 2009 Bonus Targets 
 Executive Officer 2009 Bonus Targets 
  

			
	 Executive Officer
	  	 Bonus Targets for 2009

	 P. Kay Wagoner, Ph.D., Chief Executive Officer and President
	  	Up to 50% of base salary
	 Richard D. Katz, M.D., Executive Vice President, Finance and Corporate Development, Chief Financial Officer and Treasurer
	  	Up to 40% of base salary
	 Seth V. Hetherington, Senior Vice President, Clinical and Regulatory Affairs
	  	Up to 40% of base salary

 Cash bonuses for Dr. Wagoner, Dr. Katz and Dr. Hetherington for 2009 will be based
on the achievement of specified corporate performance objectives. The corporate performance objectives for 2009 are progression of research, preclinical and clinical development programs; building shareholder confidence; achievement of corporate and
business development objectives; timely, effective and efficient completion of public company reporting obligations; and completing and maintaining policies and procedures for internal controls and compliance obligations. The actual amount of such
cash bonuses, if any, will be determined in the discretion of the Compensation Committee, subject to the maximum bonus targets shown above. The Compensation Committee will evaluate the Company’s and each executive’s performance against the
objectives listed above from time to time during 2009, and may, in its discretion, approve the payment of any bonuses in one or more installments during 2009 or in early 2010.License Agreement

 Exhibit 10.21 
 LICENSE AGREEMENT 
 This License Agreement (the “Agreement”) is made and entered into as of
November 24, 2008 (the “Effective Date”), by and between LifeNet Health, Inc., having an address of 1864 Concert Drive, Virginia Beach, VA 23453 (“LifeNet”), and RTI Biologics, Inc., having an address of 11621 Research
Circle, Alachua, FL 32615 (“RTI”). 
 WHEREAS, ************; 
 NOW THEREFORE, for the mutual promises, covenants, warranties, and agreements set forth in this Agreement, and for other good and valuable consideration,
the sufficiency of which is hereby acknowledged, LifeNet and RTI (collectively, “the Parties”; singly, “Party”) mutually covenant and agree as follows: 
 DEFINITIONS 
 “Affiliate(s)” shall mean, in relation to any Party hereto, any corporation or other
business entity presently or in the future controlled by, controlling, or under common control with that Party including (i) any subsidiary of a Party at least 50% of whose voting interest are owned or controlled directly or indirectly by that
Party and (ii) any parent entity owning or controlling directly or indirectly at least 50% of the voting interests of the Party. 
 “Covered Technology” shall mean (i) **********, including improvements and modifications thereto, used by RTI or its Affiliates in the past, present, or future; **********. 
 “LifeNet Patents” shall mean (i) U.S. Patent Nos. **********, and any LifeNet owned, controlled or future acquired domestic or
international patent related to **********, including improvements and modifications thereto; and (ii) any continuation, continuation-in-part, divisional, reissue, reexamination, application, extension or renewal patent or application and
foreign equivalent or counterpart patent or patent application to any of the foregoing, including any continuation, continuation-in-part, divisional, reissue, reexamination, application, extension or renewal patent or application claiming priority
to any of the foregoing. 
 ARTICLE 1 
 LICENSE 
 LifeNet hereby grants to RTI and its Affiliates, as well as their respective end users concerning
RTI or RTI Affiliate products and services or components thereof, an irrevocable, perpetual, non-exclusive, worldwide license under the LifeNet Patents including, without limitation, a license to make, have made, import, export, use, offer to sell
or distribute, and sell or distribute the Covered Technology. With respect to individuals or entities in the chain of distribution of RTI (or its Affiliate(s)) products and services, LifeNet further grants a limited license to those individuals and
entities to the extent reasonably necessary to carry out their tasks within the chain of distribution. The term of the License is for seven (7) years or the remaining life of any LifeNet Patent, whichever is longer. 
  

			
	The presence of asterisks (*) indicates that Confidential portions have	  	
	been omitted and filed separately with the Commission	  	CONFIDENTIAL

 1 

 ARTICLE 2 
 PAYMENTS 
 2.1 Beginning on November 26, 2008, RTI shall owe LifeNet a total of Four Million Nine Hundred Thousand U.S.
Dollars and no cents (US $4,900,000.00) to be paid in five annual installments of Nine Hundred Eighty Thousand U.S. Dollars and no cents ($980,000.00). RTI and LifeNet agree that the payment schedule for RTI’s payments to LifeNet is as follows:
November 26, 2008 ($980,000); November 25, 2009 ($980,000); November 24, 2010 ($980,000); November 23, 2011 ($980,000); and November 28, 2012 ($980,000). Upon payment of the full $4,900,000.00 to LifeNet in accordance with
this Article 2.1, all licenses, covenants, terms and conditions of this Agreement shall be deemed paid in full. RTI may, in its sole discretion, make prepayment(s) without penalty. 
 2.2 Payments shall be made via bank wire transfer to: 
  

							
	 Bank:
	  	**********	  		  	
				
	 Account Name:
	  	**********	  		  	
	 Account Number:
	  	**********	  		  	

 2.3 The Parties agree that the aforementioned installments collectively represent consideration for the
Parties’ full releases, covenants, and License as set forth in this Agreement and are not in any way representative of the value of any or all of the LifeNet Patents. 
 ARTICLE 3 
 CONFIDENTIALITY/RESTRICTED COMMUNICATIONS 
 3.1 The Parties agree that this Agreement, including the rights granted hereunder **********, are confidential (“Confidential Information”) and that the
Parties will not disclose, directly or indirectly, the terms of this Agreement, other than to their attorneys, their accountants, their tax preparers, their financial advisors, their employees or agents who need to know in the course and scope of
performing their normal job functions, and lawful taxing authorities, or unless otherwise required by law, by judicial process, or by any securities regulations, or upon the other Party’s written consent. With respect to disclosures of
Confidential Information pursuant to this Agreement, the Parties shall advise those to whom the Confidential Information is disclosed as to the confidential nature of said Confidential Information, and the Parties shall take such commercially
reasonable steps as necessary to ensure that those to whom the Confidential Information is disclosed will maintain its confidentiality to a degree at least as stringent as provided for in this Agreement. 
 3.2 Notwithstanding Article 3.1 above, the Parties agree that either Party may disclose (i) any facts publicly available as of the Effective Date, and (ii) the
terms of this Agreement as required by law or as necessary in order to enforce the terms and obligations set forth in this Agreement. In all other respects, the Parties shall keep the terms of this Agreement confidential. 
 3.3 **********. 
  

			
	The presence of asterisks (*) indicates that Confidential portions have	  	
	been omitted and filed separately with the Commission	  	CONFIDENTIAL

 2 

 3.4 Notwithstanding the foregoing, the Parties’ confidentiality and nondisclosure agreements of April 24, 2008
and June 11, 2008 remain in full effect. 
 ARTICLE 4 
 ASSIGNMENTS 
 Except in association with a merger, acquisition, change in control, or sale of all or
substantially all of RTI’s assets, RTI may not assign or transfer this Agreement without notice to and authorization by LifeNet. 
 ARTICLE 5 
 APPLICABLE LAW 
 This Agreement (and any dispute, controversy, proceedings, or claim of whatever nature arising out of or in any way relating to this Agreement) shall be governed by and construed in accordance with the laws of the
Commonwealth of Virginia. 
 ARTICLE 6 
 NOTICES AND OTHER COMMUNICATIONS 
 All notices and other communications required or permitted to be given
hereunder shall be in writing and shall be valid and sufficient if dispatched by registered airmail, prepaid airmail, prepaid air express or by facsimile (confirmed by registered or certified air mail) and shall be effective on the date of receipt
by the addressee. Such notice or communication shall be directed to: 
  

							
	 If to LifeNet:
	 		  		  	
				
	 Douglas B. Wilson
	 		  		  	
	 Executive Vice President
	 		  		  	
	 LifeNet Health, Inc.
	 		  		  	
	 1864 Concert Drive
	 		  		  	
	 Virginia Beach, VA 23453-1903
	 		  		  	
	 Fax: 757-464-5721
	 		  		  	
				
	 If to RTI:
	 		  		  	
				
	 Thomas F. Rose
	 		  	 Legal Department
	  	
	 Executive Vice President and C.F.O.
	 		  	 RTI Biologics, Inc.
	  	
	 RTI Biologics, Inc.
	 	 and
	  	 11621 Research Circle
	  	
	 11621 Research Circle
	 		  	 Alachua, FL 32615
	  	
	 Alachua, FL 32615
	 		  	 Fax: 386-418-5157
	  	
	 Fax: 386-418-0342
	 		  		  	

  

			
	The presence of asterisks (*) indicates that Confidential portions have	  	
	been omitted and filed separately with the Commission	  	CONFIDENTIAL

 3 

 ARTICLE 7 
 MISCELLANEOUS 
 7.1 LifeNet represents and warrants that: (i) LifeNet is the sole and exclusive owner of all right,
title and interest in and to the LifeNet Patents; (ii) LifeNet has the right to grant the licenses, covenants, and releases set forth in this Agreement; (iii) LifeNet, having conducted a reasonable investigation, has no known outstanding
encumbrances or agreements, including any agreements with any third parties, which would be inconsistent with the licenses, covenants, or releases set forth in this Agreement; (iv) **********; and (v), anything in this Agreement to the contrary
notwithstanding, all claims in the LifeNet Patents are valid, enforceable, and are not obvious or anticipated in light of prior art. 
 7.2 RTI agrees that
it shall make payment as provided for in Article 2 regardless of whether RTI chooses to use the LifeNet Patents. **********. 
 7.3 **********. 

7.4 RTI agrees to operate its business in compliance with the standards of the American Association of Tissue Banks and in accordance with all applicable federal,
state and local laws, rules and regulations. 
 7.5 **********. 
 7.6 This Agreement shall be treated as though having been drafted through the equal participation of both Parties, and no provision shall be interpreted against any Party on the basis that the Party is deemed to be the sole or primary
drafter of the provision. If any provision of this Agreement is determined by a court to be unenforceable, the Parties shall deem the provision to be modified to the extent necessary to allow it to be enforced to the extent permitted by law, or if
it cannot be modified, the provision or portion of a provision will be severed and deleted from this Agreement and the remainder of this Agreement will continue in effect, so long as such removal or alteration does not modify the intent of the
provision. 
 7.7 This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one
and the same instrument. A facsimile or electronically reproduced signature shall have the same force and effect as an original signature. 
 7.8 LifeNet
represents, warrants, and covenants that the person signing on behalf of LifeNet has the authority to bind LifeNet to this Agreement. RTI represents, warrants, and covenants that the person signing on behalf of RTI has the authority to bind RTI and
its Affiliates to this Agreement. 
 7.9 Article headings in this Agreement are for convenience only and are not to be construed as part of this Agreement.

 ARTICLE 8 
 **********. 
  

			
	The presence of asterisks (*) indicates that Confidential portions have	  	
	been omitted and filed separately with the Commission	  	CONFIDENTIAL

 4 

 ARTICLE 9 
 ENTIRE AGREEMENT 
 This Agreement contains the entire agreement between LifeNet and RTI and their respective
Affiliates. No modification or amendment to this Agreement, nor any waiver of any rights, will be effective unless assented to in writing by the Party to be charged, with the writing expressly identifying what it modifies or amends. A waiver of any
breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 
 IN WITNESS WHEREOF, the Parties hereto
have caused this Agreement to be executed by their respective duly authorized representatives on the date written below. 
  

									
	LIFENET HEALTH, INC.	 		 	RTI BIOLOGICS, INC.
					
	By:	 	 /s/ Douglas B. Wilson
	 		 	By:	 	 /s/ Thomas F. Rose

	Name:	 	Douglas B. Wilson	 		 	Name:	 	Thomas F. Rose
	Title:	 	Executive Vice President	 		 	Title:	 	Executive Vice President and CFO
	Date:	 	 11/24/2008
	 		 	Date:	 	 11/24/2008

  

			
	The presence of asterisks (*) indicates that Confidential portions have	  	
	been omitted and filed separately with the Commission	  	CONFIDENTIAL

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]